A three-decade series of coincidences will likely help doctors treat narcolepsy — and possibly prevent opioid addiction — and ...

(NASDAQ:GPCR) stands against the other NASDAQ stocks ... The drug was designed through the company’s structure-based drug ...

Septerna, Inc. ( (SEPN) ) has released its Q3 earnings. Here is a breakdown of the information Septerna, Inc. presented to ...

A mere six months ago Verily launched the study with Sosei Heptares – a global leader in GPCR structure-based drug design – with an aim to “prioritise protein targets for therapeutic ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Free Report) – Investment analysts at Lifesci Capital boosted their FY2024 EPS ...

Nxera Pharma & Antiverse collaborate to design novel GPCR-targeted antibody therapeutics using generative AI: Tokyo, Japan Wednesday, November 6, 2024, 13:00 Hrs [IST] Nxera Pharm ...

Phase 1a results support further development of TX000045 (“TX45”) for Group 2 Pulmonary Hypertension in HFpEF (“PH-HFpEF”), based on favorable pharmacokinetic profile and ...

Nxera Pharma (“Nxera”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – and Antiverse, a techbio company ...

Cantor Fitzgerald initiated coverage of Septerna (SEPN) with an Overweight rating and $50 price target Septerna’s powerful platform enables ...

Deep Pipeline of GPCR Programs Focused Initially on Indications in Endocrinology, Immunology and Inflammation, and Metabolic DiseasesPhase 1 ...